Related Experiment Video
Updated: Jan 9, 2026

Toeprinting Analysis of Translation Initiation Complex Formation on Mammalian mRNAs
Published on: May 10, 2018
Transcriptomic analysis reveals the potential role of TOE1 in hepatocellular carcinoma
Jie Yu Ao1,2, Yi Cai3, Si Ting Xu2
1Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, Guangdong, China.
Abstract:
This study integrates bioinformatics analysis and in vitro experiments to elucidate the role of Target of EGR1 (TOE1) in hepatocellular carcinoma (HCC) progression. TOE1, a deadenylase belonging to the DEDD exonuclease superfamily, is primarily localized in the Cajal bodies of the nucleus. While the biological functions of TOE1 have been partially characterized, its role in cancer remains unclear. We analyzed TOE1 expression, its correlation with clinicalpathological features, prognosis, and immune infiltration in HCC using databases and platforms such as The Cancer Genome Atlas (TCGA), COSMIC, cBioPortal, and TIMER. Additionally, we validated TOE1 expression levels in clinical samples. Through the knockdown of TOE1 in HCC cell lines and subsequent RNA-seq analysis, we explored its functional role and potential molecular mechanisms in HCC malignant progression. The research focused on uncovering the role of TOE1 in HCC development and its underlying mechanisms. Comprehensive bioinformatics interrogation revealed that TOE1 was significantly upregulated in HCC and was correlated with poor patient prognosis. It may influence tumor development by modulating the stemness of tumor cells and immune cell infiltration, thereby reshaping the tumor microenvironment. Furthermore, in vitro experiments suggested that TOE1 promotes HCC proliferation and metastatic potential via modulating the Hippo signaling pathway. This research highlights the pivotal role of TOE1 in HCC, indicating its promise as a novel target for early detection, therapeutic strategies, immunological intervention, and prognosis assessment in HCC. These findings provide fresh perspectives for precision medicine in the context of HCC.
Insights
Target of EGR1 (TOE1) is upregulated in hepatocellular carcinoma (HCC), promoting cancer progression and metastasis. Targeting TOE1 offers a promising strategy for HCC treatment and prognosis.
Area of Science:
- Oncology
- Molecular Biology
- Bioinformatics
Background:
- Target of EGR1 (TOE1), a nuclear deadenylase, has partially understood functions and its role in cancer is largely unknown.
- Hepatocellular carcinoma (HCC) is a major global health concern with a need for novel therapeutic targets.
Purpose of the Study:
- To investigate the role and molecular mechanisms of TOE1 in hepatocellular carcinoma (HCC) progression.
- To evaluate TOE1 as a potential biomarker for HCC diagnosis and prognosis.
Main Methods:
- Bioinformatics analysis of public databases (TCGA, COSMIC, cBioPortal, TIMER) for TOE1 expression and correlation with clinical features, prognosis, and immune infiltration in HCC.
- Validation of TOE1 expression in clinical HCC samples.
- In vitro experiments including TOE1 knockdown in HCC cell lines and RNA-seq analysis to explore functional roles and molecular pathways.
- Investigation of TOE1's modulation of the Hippo signaling pathway.
Main Results:
- TOE1 is significantly upregulated in HCC tissues compared to normal tissues.
- High TOE1 expression correlates with poor patient prognosis, advanced clinical pathological features, and altered immune cell infiltration in the tumor microenvironment.
- TOE1 knockdown inhibits HCC cell proliferation and metastasis.
- TOE1 promotes HCC progression by modulating tumor cell stemness and the Hippo signaling pathway.
Conclusions:
- TOE1 plays a critical role in HCC development and progression, acting as a potential oncogene.
- TOE1 is a promising novel target for early detection, therapeutic intervention, and prognosis assessment in HCC.
- Targeting TOE1 may offer new avenues for precision medicine strategies in HCC treatment.

